Source-grounded facts extracted from Bausch & Lomb Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Bausch & Lomb Corp shareholders approved Appointment of the Independent Registered Public Accounting Firm at the 2026-05-20 meeting.
“The shareholders appointed PricewaterhouseCoopers LLP as the auditor for the Company to hold office until the close of the 2027 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditor’s remuneration. For Withheld 343,283,263 3,986,500”
Bausch & Lomb Corp shareholders approved Advisory Vote on Executive Compensation at the 2026-05-20 meeting.
“The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Proxy Statement. For Against Abstain Broker Non-Votes 328,089,056 832,221 6,896,414 11,452,072”
Bausch & Lomb Corp shareholders approved Election of Directors at the 2026-05-20 meeting.
“The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2027 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal: For Against Broker Non-Votes Eduardo Alfonso 331,573,622 4,244,069 11,452,072 Nathalie Bernier 331,522,655 4,295,036 11,452,072 Steven H. Collis 331,575,559 4,242,132 11,452,072 Sarah B. Kavanagh 331,548,740 4,268,951 11,452,072 Karen L. Ling 331,533,402 4,284,289 11,452,072 John A. Paulson 331,537,843 4,279,848 11,452,072 Russel C. Robertson 331,561,696 4,255,995 11,452,072 Thomas W. Ross, Sr. 331,556,884 4,260,807 11,452,072 Brenton L. Saunders 331,476,725 4,340,966 11,452,072 Andrew C. von Eschenbach 331,499,049 4,318,642 11,452,072”
Bausch & Lomb Corp reported the quarter ended March 31, 2026 results: revenue $1.244 billion, net income $71 million, EPS ($0.20). Guidance raised.
“1933, as amended. --- EX-99.1 (EX-99.1) --- Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook • Revenue of $1.244 Billion • Revenue Grew 9% as Reported and 6% on a Constant Currency 1 Basis Compared to the First Quarter of 2025 • GAAP Net Loss Attributable to Bausch + Lomb Corporation of $71 Million”
Bausch & Lomb Corp amended Fourth Amendment with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank valued at $2,802,125,000 (effective 2026-01-02).
“On January 2, 2026, Bausch + Lomb Corporation (the “Company”) entered into an amendment (the “Fourth Amendment”) to the Credit and Guaranty Agreement, dated as of May 10, 2022 (as amended by the First Incremental Amendment, dated as of September 29, 2023, by the Second Incremental Amendment, dated as of November 1, 2024, by the Third Amendment, dated as of June 26, 2025, and as further amended, restated, supplemented or otherwise modified, refinanced or replaced from time to time, the “Credit Agreement”), by and among the Company, certain subsidiaries of the Company as subsidiary guarantors, the lenders and other persons party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank.”
Bausch & Lomb Corp reported the quarter ended March 31, 2024 results: revenue $1.099 billion, net income $167 million, EPS ($0.48). Guidance raised.
“statement or other document pursuant to the Securities Act of 1933, as amended. --- EX-99.1 (EX-99.1) --- Bausch + Lomb Announces First-Quarter 2024 Results • Revenue of $1.099 Billion • GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million • Adjusted EBITDA (non-GAAP) 1 of $180 Million • Revenue Grew 18% as Reported and 20% on a Constant”
Karen Ling was appointed as Director at Bausch & Lomb Corp.
“Ms. Karen Ling was appointed as a director of the Company, each effective immediately.”
Richard De Schutter retired as Member of the Board of Directors at Bausch & Lomb Corp.
“Mr. Richard De Schutter notified Bausch + Lomb Corporation (the “Company”) of his decision to not stand for re-election as a member of the Company’s Board of Directors (the “Board”) at the upcoming 2024 annual meeting of shareholders of the Company (the “2024 Annual Meeting”).”
Bausch & Lomb Corp reported financial results for the quarter and the year ended December 31, 2023.
“On February 21, 2024, Bausch + Lomb Corporation (the “Company”) issued a press release announcing results of operations for the quarter and the year ended December 31, 2023 and certain other financial information as of and for the quarter and the year ended December 31, 2023.”
Joseph Gordon resigned as President at Bausch & Lomb Corp.
“On November 6, 2023, the Company entered into a separation agreement with Mr. Gordon (the “Separation Agreement”),”
Bausch & Lomb Corp reported the quarter ended September 30, 2023 results: revenue $1.007 billion, net income $84 million. Guidance raised.
“to the Securities Act of 1933, as amended. --- EX-99.1 (EX-99.1) --- Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance • Revenues of $1.007 Billion • GAAP Net Loss Attributable to Bausch + Lomb Corporation of $84 Million • Adjusted EBITDA (non-GAAP) 1 of $187 Million • Revenues Grew 7% as Reported and 8% on a Constant”
Bausch & Lomb Corp completed an acquisition involving Novartis Pharma AG, Novartis Finance Corporation (closed 2023-09-29).
“On September 29, 2023, the Company completed the Acquisition pursuant to the terms and conditions of the previously announced Stock and Asset Purchase Agreement”
Christina Ackermann departed as other_named_officer at Bausch & Lomb Corp.
“On August 25, 2023, the Company entered into a separation agreement with Ms. Ackermann (the “Separation Agreement”), pursuant to which Ms. Ackermann is entitled to receive the following payments and benefits in accordance with the existing terms of her previously disclosed arrangements with the Company:”
Bausch & Lomb Corp reported financial results for the quarter ended June 30, 2023.
“On August 2, 2023, Bausch + Lomb Corporation (the "Company") issued a press release announcing results of operations for the quarter ended June 30, 2023 and certain other financial information as of and for the quarter ended June 30, 2023.”
Bausch & Lomb Corp entered into Stock and Asset Purchase Agreement with Novartis Pharma AG, Novartis Finance Corporation (together with Novartis Pharma AG, “Novartis”) valued at $1.75 billion (effective 2023-06-30).
“On June 30, 2023, a wholly owned subsidiary of Bausch + Lomb Corporation (the “Company” or “Bausch + Lomb”), Bausch + Lomb Ireland Limited (“Buyer”), entered into a Stock and Asset Purchase Agreement (the “Agreement”) with Novartis Pharma AG, Novartis Finance Corporation (together with Novartis Pharma AG, “Novartis”) and, solely for purposes of guaranteeing certain obligations of Buyer under the Agreement, Bausch + Lomb.”
Joseph F. Gordon changed role as strategic advisor at Bausch & Lomb Corp.
“Joseph F. Gordon will transition from his current role as President, Global Consumer, Surgical and Vision Care to the new role of strategic advisor to the Chairman and Chief Executive Officer of the Company, effective June 1, 2023.”
Bausch & Lomb Corp reported financial results for the quarter ended March 31, 2023.
“On May 3, 2023, Bausch + Lomb Corporation (the “Company”) issued a press release announcing results of operations for the quarter ended March 31, 2023 and certain other financial information as of and for the quarter ended March 31, 2023.”
Bausch & Lomb Corp shareholders approved Appointment of the Independent Registered Public Accounting Firm.
“Proposal No. 5: Appointment of the Independent Registered Public Accounting Firm. The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2024 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration. For Withheld 346,413,418 128,088”
Bausch & Lomb Corp shareholders approved Approval of an Amendment and Restatement of the Company’s 2022 Omnibus Incentive Plan to Increase the Number of Common Shares Authorized for Issuance Thereunder.
“Proposal No. 4: Approval of an Amendment and Restatement of the Company’s 2022 Omnibus Incentive Plan to Increase the Number of Common Shares Authorized for Issuance Thereunder. The shareholders approved an amendment and restatement of the Company’s 2022 Omnibus Incentive Plan. For Against Abstain Broker Non-Votes 334,690,271 9,528,109 7,201 2,315,925”
Bausch & Lomb Corp shareholders approved Advisory Vote on Frequency of Future Advisory Votes on Named Executive Officer Compensation.
“Proposal No. 3: Advisory Vote on Frequency of Future Advisory Votes on Named Executive Officer Compensation. The shareholders approved, on a non-binding advisory basis, the frequency of the shareholder vote to approve the compensation of the Company’s Named Executive Officers as described in the Proxy Statement as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 341,717,168 1,808 2,501,898 4,707 2,315,925”
Bausch & Lomb Corp shareholders approved Advisory Vote on Executive Compensation.
“Proposal No. 2: Advisory Vote on Executive Compensation. The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Proxy Statement. For Against Abstain Broker Non-Votes 338,615,408 5,599,325 10,848 2,315,925”
Bausch & Lomb Corp shareholders approved Election of Directors.
“Proposal No. 1: Election of Directors. The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2024 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal: For Against Broker Non-Votes Nathalie Bernier 344,100,848 124,733 2,315,925 Richard U. De Schutter 344,094,979 130,602 2,315,925 Gary Hu 344,016,782 208,799 2,315,925 Brett Icahn 344,072,707 152,874 2,315,925 Sarah B. Kavanagh 343,989,666 235,915 2,315,925 John A. Paulson 344,095,439 130,142 2,315,925 Russel C. Robertson 344,098,056 127,525 2,315,925 Thomas W. Ross, Sr. 340,211,351 4,014,230 2,315,925 Brenton L. Saunders 342,408,245 1,817,336 2,315,925 Andrew C. von Eschenbach 343,985,915 239,666 2,315,925”
Andrew Stewart was appointed as President, Ophthalmic Pharmaceuticals at Bausch & Lomb Corp.
“Andrew Stewart will be appointed as the Company’s President, Ophthalmic Pharmaceuticals”
A. Robert D. Bailey was appointed as Executive Vice President & Chief Legal Officer at Bausch & Lomb Corp.
“A. Robert D. Bailey will be appointed as the Company’s Executive Vice President & Chief Legal Officer”
Christina M. Ackermann departed as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals at Bausch & Lomb Corp.
“On April 12, 2023, Bausch + Lomb Corporation (the “Company”) announced the upcoming departure of Christina M. Ackermann as Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals of the Company.”
Bausch & Lomb Corp reported financial results for the quarter and the year ended December 31, 2022.
“On February 22, 2023, Bausch + Lomb Corporation (the “Company”) issued a press release announcing results of operations for the quarter and the year ended December 31, 2022 and certain other financial information as of and for the quarter and the year ended December 31, 2022.”
Thomas W. Ross, Sr. changed role as Lead Independent Director at Bausch & Lomb Corp.
“Effective upon Mr. Saunders’ appointment as Chair of the Board on the Transition Date, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board.”
Joseph C. Papa departed as Chief Executive Officer at Bausch & Lomb Corp.
“Joseph C. Papa will step down from his roles as Chief Executive Officer and member of the board of directors of the Company (the “Board”).”
Brent Saunders was appointed as Chief Executive Officer and Chair at Bausch & Lomb Corp.
“On February 15, 2023, Bausch + Lomb Corporation (the “Company”) announced the appointment of Brent Saunders as Chief Executive Officer of the Company, effective March 6, 2023 (the “Transition Date”).”
Joseph C. Papa departed as Chief Executive Officer at Bausch & Lomb Corp.
“Mr. Papa agreed to continue serving as Chief Executive Officer until at least March 4, 2023”
Bausch & Lomb Corp reported financial results for the quarter ended September 30, 2022.
“On November 2, 2022, Bausch + Lomb Corporation (the “Company”) issued a press release announcing results of operations for the quarter ended September 30, 2022 and certain other financial information as of and for the quarter ended September 30, 2022.”
Joseph C. Papa departed as Chief Executive Officer at Bausch & Lomb Corp.
“the recently announced upcoming departure of our current Chief Executive Officer (Joseph C. Papa)”
Thomas W. Ross, Sr. was appointed as Chairperson of the Board at Bausch & Lomb Corp.
“Chairperson: Thomas W. Ross, Sr.”
Joseph C. Papa departed as Chief Executive Officer at Bausch & Lomb Corp.
“Joseph C. Papa will continue serving as Chief Executive Officer until his successor is appointed”
Gary Hu was appointed as Director at Bausch & Lomb Corp.
“the size of the Board was increased to ten and Brett Icahn and Gary Hu were appointed to the Board, effective immediately.”
Brett Icahn was appointed as Director at Bausch & Lomb Corp.
“the size of the Board was increased to ten and Brett Icahn and Gary Hu were appointed to the Board, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.